Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Psilocybin-induced behavioral and cellular effects. Psilocybin · PMID 42437560 | Maladie d’Alzheimer · Cancer · Migraine · Maladie de Parkinson · Sclé… | À vérifier | Publication | PubMed | Voir la publication source Psilocybin, a prominent psychedelic, recently emerged as a potential therapeutic agent for psychiatric disorders, yet t… | Journal of neurogenetics 2026-07-14 16:28:39 | Source |
| [Effectiveness of plasmapheresis in adolescent myasthenia gravis trea… Ocular Mysathenia Gravis Generalization · PMID 21442979 | Myasthénie | Immunomodulation · Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Myasthenia gravis (MG) is a disease with autoimmune background. Impaired neuromuscular transmission is caused by blocka… | Przeglad lekarski 2026-07-14 16:28:33 | Source |
| Clinical course of critical demyelinating lesion-associated progressi… Ravulizumab · PMID 42440141 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Progressive multiple sclerosis (MS) is usually associated with progressive asymmetrical motor impairment. A single crit… | Journal of neurology 2026-07-14 16:28:22 | Source |
| Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive N… Ravulizumab · PMID 42441931 | Myasthénie | Thérapie génique | Publication | PubMed | Voir la publication source Ravulizumab, a complement component 5 inhibitor, was approved for the treatment of adults with anti-aquaporin-4 antibod… | Neurology(R) neuroimmunology & neuroinflammation 2026-07-14 16:28:22 | Source |
| Trunk-oriented Exercises Versus Whole-body Vibration on Abdominal Thi… Trunk Oriented Exercises Versus Whole-body Vibration for Duchenne Muscular Dystrophy · PMID 38… | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Progressive proximal muscle weakening in children with Duchenne muscular dystrophy (DMD) impairs postural adjustments b… | Journal of musculoskeletal & neuronal interactions 2026-07-14 16:28:20 | Source |
| "Nothing about us without us": Co-production of and 'How To' implemen… Pain Science Education · PMID 42345107 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Temporomandibular disorders (TMDs) affect up to 1 in 15 people, significantly impairing daily function and quality of l… | Primary dental journal 2026-07-14 16:28:18 | Source |
| Smallest Detectable Change of the Knowledge and Attitudes of Pain in… Pain Science Education · PMID 42333373 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Background Pain Science Education (PSE) aims to improve patients' understanding of pain based on modern pain science, e… | Cureus 2026-07-14 16:28:18 | Source |
| Topical resiniferatoxin for the treatment of vestibulodynia: a prospe… Capsaicin Topical Cream · PMID 42434379 | Myopathies | Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source Vestibulodynia is the most common subtype of vulvodynia and is characterized by persitent, contact-evoked pain localize… | AJOG global reports 2026-07-14 16:28:02 | Source |
| Interesting neuroimaging findings in a child with hyperlipidemia: a c… MRI, Venipuncture · PMID 42035053 | Lupus | À vérifier | Publication | PubMed | Voir la publication source INTRODUCTION: Neurological manifestations are rare in hyperlipidemia; however, extreme hypertriglyceridemia may cause “… | BMC pediatrics 2026-07-14 16:27:45 | Source |
| Nurse led first seizure clinics-a dangerous experiment or an effectiv… MRI, Venipuncture · PMID 42208389 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source In the United Kingdom (UK), people experiencing a suspected first seizure should be seen by a clinician with expertise… | Epilepsy & behavior : E&B 2026-07-14 16:27:45 | Source |
| Interfacial-Electronegativity-Induced Near-Surface Tetrahedral Recons… Anti-CD19-CD3E-CAR-T cells · PMID 42444528 | Lupus | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Direct upcycling of spent lithium iron phosphate (S-LFP) into high-rate cathodes is highly desirable yet remains challe… | Advanced materials (Deerfield Beach, Fla.) 2026-07-14 16:27:41 | Source |
| EEG emotion recognition using a channel-aware feature encoder and XGB… EEG · PMID 42444312 | Maladie d’Alzheimer · Épilepsie · Lupus · Lupus · Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Electroencephalogram (EEG)-based emotion recognition is hindered by a low signal-to-noise ratio, inter-subject variabil… | Computer methods in biomechanics and biomedical engine… 2026-07-14 16:27:35 | Source |
| Successful transcranial motor evoked potentials monitoring under remi… EEG · PMID 42444469 | Maladie d’Alzheimer · Épilepsie · Lupus · Lupus · Épilepsie | Thérapie génique | Publication | PubMed | Voir la publication source Intraoperative neurophysiological monitoring is a standard in surgeries with an increased risk of iatrogenic neurologic… | Biomedical papers of the Medical Faculty of the Univer… 2026-07-14 16:27:35 | Source |
| Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guidelin… liposomal doxorubicin · PMID 42441925 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial… | Journal of clinical oncology : official journal of the… 2026-07-14 16:27:23 | Source |
| Advances in targeted therapy for triple-negative breast cancer: a rev… Sacituzumab govitecan-hziy · PMID 40515614 | Cancer | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source The most aggressive subtype of breast cancer is triple-negative breast cancer (TNBC), which affects about 10-15% of all… | Journal of drug targeting 2026-07-14 16:27:22 | Source |
| Sacituzumab-induced severe or febrile neutropenia and G-CSF utilizati… Sacituzumab govitecan-hziy · PMID 41991763 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Severe neutropenia (SN) and febrile neutropenia (FN) are clinically significant safety concerns of sacituzumab goviteca… | Breast cancer research and treatment 2026-07-14 16:27:22 | Source |
| From pulmonary embolism to small intestinal neuroendocrine tumor: A n… Octreotide Acetate · PMID 42438425 | Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source Pulmonary embolism is a common and potentially life-threatening acute condition encountered in clinical practice. Neuro… | The Journal of international medical research 2026-07-14 16:27:18 | Source |
| Efficacy at a cost: camrelizumab and famitinib within the expanding l… Camrelizumab · PMID 42428453 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Gynecology and pelvic medicine 2026-07-14 16:27:17 | Source |
| Immune checkpoint inhibitor integration in locoregionally advanced na… Camrelizumab · PMID 42433378 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Several prospective and randomized trials support immune checkpoint inhibitors (ICIs) as an emerging component of stand… | Frontiers in immunology 2026-07-14 16:27:17 | Source |
| Intra-articular VEGF inhibition attenuates cartilage degeneration in… Bevacizumab · PMID 42443550 | Cancer · Maladie de Parkinson · Cancer | À vérifier | Publication | PubMed | Voir la publication source Osteoarthritis (OA) is a progressive joint disease characterized by cartilage degeneration, subchondral bone remodellin… | Rheumatology international 2026-07-14 16:27:12 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||